Skip to content

Study · Observational study · n = 80 · 2026

7 results

Impact of Preoperative Semaglutide Discontinuation Timing on Postoperative Outcomes in Aesthetic Abdominoplasty: A Retrospective Comparative Study.

Bruno A, Calicchia A, Schirosi M

Aesthetic plastic surgery12 Jun 2026

PMID42286330 (opens in a new tab)DOI10.1007/s00266-026-05978-x (opens in a new tab)PepBankPUB-42286330
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studySafety outcome

    In patients having lipoabdominoplasty, gastrointestinal intolerance was more frequent with ongoing semaglutide use.

    In plain wordsIn patients having abdominal surgery, stomach and gut problems were more common in those still taking semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal intolerance
    Study

    n = 80

    Comparator
    Patients without ongoing semaglutide use
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Gastrointestinal intolerance and prolonged drain duration were also more frequent in patients with ongoing semaglutide use.
    1 context sentence
    Summary · context
    Eighty patients who underwent primary lipoabdominoplasty were divided into four groups: continued semaglutide until surgery (Group A), 2-week discontinuation (Group B), 4-week discontinuation (Group C), and semaglutide-naïve controls (Group D).
  2. 02HumanObservational studySafety outcome

    In patients having lipoabdominoplasty, prolonged drain duration was more frequent with ongoing semaglutide use.

    In plain wordsIn patients having abdominal surgery, drains stayed in longer more often in those still taking semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseDrain duration
    Study

    n = 80

    Comparator
    Patients without ongoing semaglutide use
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Gastrointestinal intolerance and prolonged drain duration were also more frequent in patients with ongoing semaglutide use.
    1 context sentence
    Summary · context
    Eighty patients who underwent primary lipoabdominoplasty were divided into four groups: continued semaglutide until surgery (Group A), 2-week discontinuation (Group B), 4-week discontinuation (Group C), and semaglutide-naïve controls (Group D).
  3. 03HumanObservational studySafety outcome

    In patients having lipoabdominoplasty, no reoperations occurred.

    In plain wordsIn patients having abdominal surgery, none needed a second operation.

    Peptide
    Semaglutide
    Outcome
    No significant changeReoperations
    Study

    n = 80

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No reoperations or readmissions occurred.
    1 context sentence
    Summary · context
    Eighty patients who underwent primary lipoabdominoplasty were divided into four groups: continued semaglutide until surgery (Group A), 2-week discontinuation (Group B), 4-week discontinuation (Group C), and semaglutide-naïve controls (Group D).
  4. 04HumanObservational studySafety outcome

    In patients having lipoabdominoplasty, no readmissions occurred.

    In plain wordsIn patients having abdominal surgery, none returned to hospital.

    Peptide
    Semaglutide
    Outcome
    No significant changeReadmissions
    Study

    n = 80

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No reoperations or readmissions occurred.
    1 context sentence
    Summary · context
    Eighty patients who underwent primary lipoabdominoplasty were divided into four groups: continued semaglutide until surgery (Group A), 2-week discontinuation (Group B), 4-week discontinuation (Group C), and semaglutide-naïve controls (Group D).
  5. 05HumanObservational studySafety outcome

    In patients having lipoabdominoplasty, continuing semaglutide until surgery gave a complication rate of 45%, versus 10% in semaglutide-naive controls.

    In plain wordsIn patients having abdominal surgery, those who kept taking semaglutide until surgery had more complications (45%) than patients who never took it (10%).

    Peptide
    Semaglutide
    Outcome
    Increase30-day postoperative complication rate, semaglutide continued until surgery
    Study

    n: not reported in source

    Comparator
    Semaglutide-naive controls (Group D)
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Complication rate
    45%
    Group A, semaglutide continued
    Complication rate
    10%
    Group D, controls

    Source sentences

    Summary
    Group A exhibited the highest complication rate (45%), including wound dehiscence, infection, and seroma formation. Group B showed moderate improvement (30% complication rate), while Group C demonstrated a significant reduction in adverse outcomes (10%), comparable to the control group (10%).
    1 context sentence
    Summary · context
    Eighty patients who underwent primary lipoabdominoplasty were divided into four groups: continued semaglutide until surgery (Group A), 2-week discontinuation (Group B), 4-week discontinuation (Group C), and semaglutide-naïve controls (Group D).
  6. 06HumanObservational studySafety outcome

    In patients having lipoabdominoplasty, stopping semaglutide 2 weeks before surgery gave a complication rate of 30%, lower than the 45% with continued use.

    In plain wordsIn patients having abdominal surgery, stopping semaglutide 2 weeks before surgery gave fewer complications (30%) than continuing it (45%).

    Peptide
    Semaglutide
    Outcome
    Decrease30-day postoperative complication rate, 2-week semaglutide discontinuation
    Study

    n: not reported in source

    Comparator
    Semaglutide continued until surgery (Group A)
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Complication rate
    30%
    Group B, 2-week discontinuation

    Source sentences

    Summary
    Group B showed moderate improvement (30% complication rate)
    2 context sentences
    Summary · context
    Group A exhibited the highest complication rate (45%), including wound dehiscence, infection, and seroma formation.
    Summary · context
    Eighty patients who underwent primary lipoabdominoplasty were divided into four groups: continued semaglutide until surgery (Group A), 2-week discontinuation (Group B), 4-week discontinuation (Group C), and semaglutide-naïve controls (Group D).
  7. 07HumanObservational studySafety outcome

    In patients having lipoabdominoplasty, stopping semaglutide 4 weeks before surgery gave a complication rate of 10%, comparable to semaglutide-naive controls (10%).

    In plain wordsIn patients having abdominal surgery, stopping semaglutide 4 weeks before surgery gave complication rates similar to patients who never took it.

    Peptide
    Semaglutide
    Outcome
    No significant change30-day postoperative complication rate, 4-week semaglutide discontinuation
    Study

    n: not reported in source

    Comparator
    Semaglutide-naive controls (Group D)
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Complication rate
    10%
    Group C, 4-week discontinuation

    Source sentences

    Summary
    Group C demonstrated a significant reduction in adverse outcomes (10%), comparable to the control group (10%).
    1 context sentence
    Summary · context
    Eighty patients who underwent primary lipoabdominoplasty were divided into four groups: continued semaglutide until surgery (Group A), 2-week discontinuation (Group B), 4-week discontinuation (Group C), and semaglutide-naïve controls (Group D).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.